Premium
An integrative biology approach for analysis of drug action in models of human vascular inflammation
Author(s) -
Kunkel Eric J.,
Dea Marlene,
Ebens Allen,
Hytopoulos Evangelos,
Melrose Jennifer,
Nguyen Dat,
Ota Ken S.,
Plavec Ivan,
Wang Yuker,
Watson Susan R.,
Butcher Eugene C.,
Berg Ellen L.
Publication year - 2004
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.04-1538fje
Subject(s) - calcineurin , drug , drug discovery , inflammation , pharmacology , disease , computational biology , biology , drug development , immune system , probucol , hmg coa reductase , medicine , bioinformatics , immunology , reductase , cholesterol , biochemistry , enzyme , transplantation
Unexpected drug activities discovered during clinical testing establish the need for better characterization of compounds in human disease‐relevant conditions early in the discovery process. Here, we describe an approach to characterize drug function based on statistical analysis of protein expression datasets from multiple primary human cell‐based models of inflammatory disease. This approach, termed Biologically Multiplexed Activity Profiling (BioMAP), provides rapid characterization of drug function, including mechanism of action, secondary or off‐target activities, and insights into clinical phenomena. Using three model systems containing primary human endothelial cells and peripheral blood mononuclear cells in different environments relevant to vascular inflammation and immune activation, we show that BioMAP profiles detect and discriminate multiple functional drug classes, including glucocorticoids; TNF‐α antagonists; and inhibitors of HMG‐CoA reductase, calcineurin, IMPDH, PDE4, PI‐3 kinase, hsp90, and p38 MAPK, among others. The ability of cholesterol lowering HMG‐CoA reductase inhibitors (statins) to improve outcomes in rheumatic disease patients correlates with the activities of these compounds in our BioMAP assays. In addition, the activity profiles identified for the immunosuppressants mycophenolic acid, cyclosporin A, and FK‐506 provide a potential explanation for a reduced incidence of posttransplant cardiovascular disease in patients receiving mycophenolic acid. BioMAP profiling can allow integration of meaningful human biology into drug development programs.